🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

The Effect of Anti-IL17 on Airway Hyperresponsiveness and Resistance

Recruitingn/aAges 18 Years - anyAllCopenhagen University Hospital, Hvidovre
NCT06224634 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This observational longitudinal cohort study aims to assess the effect of monoclonal antibodies targeting interleukin 17 (anti-IL-17) on airway hyperreactivity and airway resistance. The study involves adult participants suffering from dermatological or rheumatological illness, who are planning to start treatment with monoclonal antibodies targeting interleukin 17 as a part of the treatment of these diseases. The primary outcome of this study will be changes in airway hyperresponsiveness to methacholine challenge reported as response-dose-ratio before and after initiation of anti-IL17 treatment regardless of presence of respiratory disease. Furthermore, the potential effect of anti-IL-17 on airway resistance will be assessed using conventional spirometry for measuring changes in FEV1 and Airwave oscillometry. A reduced degree of airway hyperreactivity and airway resistance after initia

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients planning to start treatment with anti-IL-17 antibodies Exclusion Criteria: * Current pregnancy * FEV1 \< 1.5L or less than 60% of predicted value expected. * Previous anaphylactic shock or severe allergic reaction to medicine * Uncontrolled hypertension * Myocardial infarction or stroke within the last 3 months * Known aortic aneurysm * Recent eye surgery or risk of elevated intracranial pressure * Treatment with systemic corticosteroids within 6 weeks
💊

What it tests

  • Not listed
📍

Where

1 site
Respiratory Research Unit Hvidovre Department of Respiratory Medicine, Copenhagen University Hospital
Hvidovre, Denmark
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy